First Trust Advisors LP Acquires 1,305 Shares of Eli Lilly and Company $LLY
Cardiovascular disease biotech Scribe Therapeutics prices upsized IPO at $15, the high end of the range
Lilly Targets Early 2027 Filing for Next Obesity Drug
Eli Lilly's Retatrutide Meets Primary Endpoint In Phase 3 TRIUMPH-2 And TRIUMPH-3 Trials
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
HBM Healthcare swings to CHF 238 million Q1 FY27 profit; NAV per share rises 13%